Development and validation of GCHSmethod used for trace level determination of carcinogenic Epichlorohydrin impurity in Rivaroxaban
DOI:
https://doi.org/10.22270/ajprd.v10i3.1123Keywords:
Rivaroxaban, genotoxic, Epichlorohydrin, impurity, development, and validationAbstract
A simple, sensitive, and selective Headspace-Gas chromatography (GCHS) method was developed and validated for the trace level determination of Epichlorohydrin, which is a probable carcinogenic compound and may be present as a process impurity in Rivaroxaban drug substances. Identification and separation of analytes were achieved on a DB-Wax column having dimensions of 30 m in length and a 0.53 mm internal diameter with a 1.0 μm stationary film thickness. Nitrogen is used as a carrier gas with of flow rate of 6.0 mL/min. The run time of the method is 25 minutes. The gradient column oven-temperature programming method was used for analyte elution. The developed method was validated using ICH guidelines and found a linear in the range between 9.64 ppm and 80.31 ppm. The correlation coefficient and y-intercept observed for the linearity curve are 0.9993 and 1.75%, respectively. The limit of detection and quantitation were 3.03 ppm and 9.19 ppm, respectively. Recovery was observed for Epichlorohydrin between 94.66 % and 99.22 %. The RSD for system precision, precision at LOQ, and repeatability was less than 5.0 %. The developed method can be successfully applied to determine Epichlorohydrin in Rivaroxaban drug substances up to a very low trace level concentration. The method was found to be specific, selective, linear, precise, and accurate.
Downloads
References
2. Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor Xa inhibitor. Arteriosclerosis, thrombosis, and vascular biology. 2010; 30(3):376-381.
3. International Agency for Research on Cancer. Epichlorohydrin. IARC Summary & Evaluation, No. 71. http://www. inchem. org/documents/iarc/vol71/020-epichlorohydrin. html. 1999; 603.
4. Guideline, ICH Harmonized Tripartite. Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic RISK M7. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use (ICH): Geneva. 2014.
5. Snodin DJ, McCrossen SD. Guidelines and pharmacopoeial standards for pharmaceutical impurities: overview and critical assessment. Regulatory Toxicology and Pharmacology. 2012; 63(2):298-312.
6. Chan CC, Lee YC, Lam H, Zhang XM. Analytical method validation and instrument performance verification. John Wiley & Sons; 2004. p. 23.
7. Guideline ICH. Validation of analytical procedures: text and methodology Q2 (R1). International conference on harmonization, Geneva, Switzerland 2005 Nov (pp. 11-12).
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.